Uncategorized

Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.

Eighteen blue state governors are warning of a looming affordability cliff for millions of Americans if lawmakers allow generous financial assistance to lapse at the end of this year.

A decade-long journey is coming to an end for Stealth BioTherapeutics and the Barth syndrome community. Will it result in the first-ever treatment for this ultra-rare mitochondrial disease, or possibly the end of the road for the Massachusetts-based biotech?

The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to counteract past tolerability issues.

A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain populations marred the gene therapy’s record.

States have been anticipating more details about the Rural Health Transformation Fund since July. Now, they will have until Nov. 5 to submit applications for a piece of the $50 billion dollar pie.

Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.

A two-day meeting could prove an inflection point in HHS Secretary’s Kennedy’s efforts to overhaul U.S. vaccine policy, as hand-picked advisers are set to vote on guidelines for measles, hepatitis B and COVID shots.

Some firms, such as Aidoc, are working directly with the FDA. Others, such as HOPPR, are offering their foundation models for medtech companies to build their own AI tools. 

Major physician groups and specialists commented in droves that regulators missed the mark on the Medicare physician fee schedule for next year.